Stryker has been under pressure after a sharp share price pullback and fresh headlines about extended manufacturing problems, which puts a spotlight on whether the current valuation can still be explained by the cash the business is expected to generate. With the stock now well below where it traded a year ago, investors are increasingly asking if the recent news flow is fully reflected in the price or if the cash flow story points to something different.
For investors, the debate is whether Stryker's current share price is adequately supported by the cash flows implied by a Discounted Cash Flow (DCF) view of the business.
To understand Stryker's cash flow debate in the context of other opportunities based on intrinsic value, it can be useful to compare it with 27 high quality undervalued stocks.
The Discounted Cash Flow (DCF) model here uses a 2 Stage Free Cash Flow to Equity approach that projects what Stryker might return to shareholders over time based on its cash generation. Latest twelve month free cash flow sits at about $4.7b, and the model assumes these owner earnings keep growing over the next decade rather than shrinking or stalling.
Across the projection window, forecast free cash flows are expected to trend higher in dollar terms. This supports an intrinsic value that the DCF framework views as meaningfully above the current $285.22 share price. The extended manufacturing issues in the Peripheral Vascular unit and the related investigation help explain why the market keeps the valuation in check even while the cash flow profile in the model remains constructive. Find out what Stryker could be worth using our Discounted Cash Flow (DCF) estimate.
Narratives on Simply Wall St take the DCF puzzle around Stryker a step further by spelling out which paths for revenue, profitability and earnings would need to occur for the share price to sit meaningfully above or below where it trades today, and they sit within the platform's Community page. Rather than leaning on a single multiple or model output, each scenario lays out the assumptions behind its fair value view so you can compare those expectations with Stryker's reported numbers over time.
One of the top community narratives on Stryker: 23% undervalued
"Stryker needs continued strong uptake of Mako systems and Smart Care offerings, together with effective execution on manufacturing and supply chain changes..."
Discover why this Narrative puts Stryker at 23% undervalued.
Before leaning too heavily on any intrinsic value view for Stryker, it helps to know that Simply Wall St's broader checks have already highlighted specific areas of concern that deserve your attention. Take a closer look at 2 warning signs before settling on a valuation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com